Loading organizations...
§ Private Profile · Menlo Park, CA, USA
Medical device company developing mechanical thrombectomy devices for VTE clot removal, focused on single-pass peripheral solutions.
Based in Menlo Park, California, Endovascular Engineering develops mechanical thrombectomy devices designed for clot removal in venous thromboembolism, deep vein thrombosis, and pulmonary embolism. The medical device manufacturer advances single-pass peripheral thrombectomy solutions from preclinical development toward clinical application for interventional cardiologists and radiologists treating vascular conditions. Operating with fewer than 25 employees and generating under $5 million in annual revenue, the enterprise recently appointed Dan Rose as its new chief executive officer. The firm secured a $42 million oversubscribed Series B financing round in February 2025, building upon a previous $15 million Series A1 equity investment. This capitalization was supported by a syndicate of institutional investors and strategic partners, including Santé Ventures, 415 Capital, S3 Ventures, and Cordis. Endovascular Engineering was established in 2019 by founder and chief scientific officer Luis Savastano.
Endovascular Engineering has raised $57.0M across 2 funding rounds.
Endovascular Engineering has raised $57.0M in total across 2 funding rounds.
Endovascular Engineering (E2) is a venture-funded medical device startup based in Menlo Park, California, developing innovative thrombectomy systems for venous thromboembolism (VTE), including pulmonary embolism (PE).[1][2][3][5] The company builds the Hēlo™ Thrombectomy System, a small-profile catheter with a self-expanding funnel design that enables large-bore clot engagement through high-speed agitation and physician-controlled aspiration, serving hospitals and clinicians treating critical vascular clot conditions.[1][4][5] It addresses limitations of existing devices by combining small-profile navigation in complex anatomies with effective single-pass clot removal, improving patient outcomes in VTE cases; the firm has raised $42M in Series B funding and advanced from preclinical to pivotal clinical trials like ENGULF, with enrollment completed in 2025.[1][2][4]
Founded in 2019, Endovascular Engineering emerged from expertise in vascular interventions, led by Luis Savastano as Founder and President, with Dan Rose as CEO.[2] The idea stemmed from unmet needs in mechanical thrombectomy for peripheral and venous indications, particularly VTE, where current tools struggle with clot burden in challenging anatomies.[1][2][3] Early traction included transitioning from stealth/preclinical stages to positive ENGULF feasibility results in 2024 and pivotal cohort enrollment completion for PE treatment by June 2025, alongside appointing a CFO in September 2025 to fuel growth.[2][4]
Endovascular Engineering rides the VTE treatment boom, driven by rising PE incidence and demand for minimally invasive catheter-based solutions over surgery or thrombolytics.[1][3][5] Timing aligns with post-pandemic clot surges and regulatory tailwinds for next-gen devices, as market forces favor agile systems reducing procedure times and complications amid aging populations.[2][4] It influences medtech by bridging small- and large-bore tech, potentially setting standards for PE/VTE care and attracting partnerships with larger firms.[1][5]
With pivotal ENGULF data presented at VIVA 2025 and a new CFO steering commercialization, E2 is poised for FDA clearance and market entry in 2026-2027.[2] Trends like AI-guided imaging and expanded VTE indications will amplify its trajectory, evolving its role from innovator to ecosystem shaper via acquisitions or IPO. This positions Endovascular Engineering as a high-momentum player redefining vascular thrombectomy, enhancing outcomes where clots threaten lives.[1][2][5]
Endovascular Engineering has raised $57.0M in total across 2 funding rounds.
Endovascular Engineering's investors include Grayhawk Capital, RiverVest, S3 Ventures, Sante Ventures.
Endovascular Engineering has raised $57.0M across 2 funding rounds. Most recently, it raised $42.0M Series B in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2025 | $42M Series B | Grayhawk Capital | Rivervest, S3 Ventures | Announced |
| Apr 6, 2022 | $15M Series A | Sante Ventures | — | Announced |